News
ZNTL
11.06
+0.68%
0.08
Zentalis Pharmaceuticals Becomes Oversold (ZNTL)
NASDAQ · 9h ago
Weekly Report: what happened at ZNTL last week (0415-0419)?
Weekly Report · 4d ago
Weekly Report: what happened at ZNTL last week (0408-0412)?
Weekly Report · 04/15 11:48
Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling
Zentalis Pharmaceuticals, Inc. Expects final results from phase 1b study of azenosertib for the treatment of patients with osteosarcoma in the 1st half of 2024. Zentalis is working on advancing its lead candidate in its pipeline. The drug could be approved for a gynecological indication in 2026.
Seeking Alpha · 04/12 18:12
Zentalis Shares Fall After Chief Financial Officer Resigns
Zentalis Pharmaceuticals shares are down 8.4% to $13.49. Melissa Epperly resigned as chief financial officer, treasurer and accounting officer. The company didn't specify the reason for her departure. Zentalis is a clinical-stage biopharmaceutical company.
Dow Jones · 04/11 15:09
Zentalis Pharmaceuticals says Melissa Epperly resigns as CFO
Healthcare Zentalis Pharmaceuticals says Melissa Epperly resigns as CFO. The company has appointed president, Cam Gallagher, as interim CFO to replace her. The firm is also conducting a search for a new finance chief. Zental is Pharmaceuticals, Inc. (ZNTL)
Seeking Alpha · 04/11 11:33
Zentalis Pharmaceuticals Announces Executive Financial Transition
TipRanks · 04/11 11:12
ZENTALIS PHARMACEUTICALS INC - ON APRIL 5, MELISSA EPPERLY RESIGNED AS CHIEF FINANCIAL OFFICER OF ZENTALIS PHARMACEUTICALS EFFECTIVE IMMEDIATELY
Reuters · 04/11 11:02
ZENTALIS PHARMACEUTICALS INC - BOARD APPOINTED COMPANY'S PRESIDENT, CAM GALLAGHER, AS INTERIM CHIEF FINANCIAL OFFICER
Reuters · 04/11 11:02
Zentalis Pharmaceuticals to Present at Upcoming Conferences
TipRanks · 04/09 20:43
Weekly Report: what happened at ZNTL last week (0401-0405)?
Weekly Report · 04/08 11:54
Zentalis Pharmaceuticals To Highlight Preclinical Data Demonstrating That WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-Tumor Activity With KRAS(G12C) Inhibitors At AACR Annual Meeting 2024
Azenosertib exerts synergistic anti-tumor activity when combined with KRASG12C inhibitors. Zentalis will present preclinical data at the 2024 Annual Meeting of the American Association for Cancer Research in San Diego. The Company's WEE1 inhibitor is a potent and selective inhibitor of the cell cycle regulator.
Benzinga · 04/02 20:07
ZENTALIS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 04/01 21:30
Weekly Report: what happened at ZNTL last week (0325-0329)?
Weekly Report · 04/01 11:51
PLAB, SMTC and WOOF are among after hour movers
On the Move PLAB, SMTC and WOOF are among after hour movers. Semtech Corporation, ANAB and ZNTL are among the biggest gainers in the biotech sector. PLAB and SMTC were among the largest losers in the pharmaceutical sector.
Seeking Alpha · 03/28 20:52
12 Health Care Stocks Moving In Thursday's After-Market Session
Qilian Intl Hldg Gr (NASDAQ:QLI) shares increased by 73.2% to $1.1 during Thursday's after-market session. Dare Bioscience stock rose 12.19% and Sunshine Biopharma stock increased by 37.85%. Vivos Therapeutics stock fell 12.6% as the company's Q4 earnings came out today.
Benzinga · 03/28 20:31
Weekly Report: what happened at ZNTL last week (0318-0322)?
Weekly Report · 03/25 11:54
Weekly Report: what happened at ZNTL last week (0311-0315)?
Weekly Report · 03/18 11:52
FLEX, OCUL and PRPL are among after hour movers
On the Move FLEX, OCUL and PRPL are among after hour movers. ESAC, CTMX, ENCP and XPDB are among the biggest losers in the biotech sector. The market is moving in the right direction.
Seeking Alpha · 03/11 20:46
Weekly Report: what happened at ZNTL last week (0304-0308)?
Weekly Report · 03/11 11:48
More
Webull provides a variety of real-time ZNTL stock news. You can receive the latest news about Zentalis Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ZNTL
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.